H.C. Wainwright Believes Provention Bio (PRVB) Still Has Room to Grow
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Provention Bio (PRVB) today and set a price target of $26.00. The company’s shares closed last Monday at $18.26, close to its 52-week high of $19.19.
According to TipRanks.com, Selvaraju is a 5-star analyst with an average return of 23.4% and a 62.0% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Taro Pharmaceutical Industries, Protalix Biotherapeutics, and NeuroBo Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Provention Bio with a $28.75 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $19.19 and a one-year low of $4.72. Currently, Provention Bio has an average volume of 503.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D); PRV-015 for the treatment of gluten-free diet non-responding celiac disease; PRV-6527 for Crohn’s disease; PRV-300 for ulcerative colitis; PRV-3279 for the treatment of lupus; and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of T1D onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Lebanon, NJ.
Read More on PRVB: